AFAP1-AS1

Summary

AFAP1-AS1 (AFAP1 antisense RNA 1, HGNC:28141) is a long non-coding RNA gene on chromosome 4p16.1.

This gene produces a long non-coding RNA that is overexpressed in tumor cells and may promote cancer cell metastasis.

Source: NCBI Gene 84740 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28141
Approved symbol	AFAP1-AS1
Name	AFAP1 antisense RNA 1
Location	4p16.1
Locus type	RNA, long non-coding
Status	Approved
Aliases	ATMLP, MGC10981
Ensembl gene	ENSG00000272620
Ensembl biotype	lncRNA
OMIM	619779
Entrez	84740
RNAcentral	URS000075E0F9 — lncRNA, 6810 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 lncRNA

ENST00000608442, ENST00000674004

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000608442 — 2 exons

Exon	Start	End
ENSE00003711455	7772204	7778928
ENSE00003896823	7754077	7754159

Expression profiles

Bgee: expression breadth ubiquitous, 162 present calls, max score 83.43.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.4571 / max 158.2463, expressed in 116 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
46836	1.4571	116

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	83.43	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.58	silver quality
oocyte	CL:0000023	77.07	gold quality
buccal mucosa cell	CL:0002336	74.76	gold quality
cortical plate	UBERON:0005343	73.04	gold quality
stromal cell of endometrium	CL:0002255	72.87	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	70.84	gold quality
left ovary	UBERON:0002119	70.08	gold quality
right ovary	UBERON:0002118	69.74	gold quality
bone marrow cell	CL:0002092	69.55	silver quality
pancreatic ductal cell	CL:0002079	69.36	silver quality
ganglionic eminence	UBERON:0004023	68.90	gold quality
ventricular zone	UBERON:0003053	68.25	gold quality
muscle layer of sigmoid colon	UBERON:0035805	67.67	gold quality
left uterine tube	UBERON:0001303	67.50	gold quality
ovary	UBERON:0000992	66.81	gold quality
colonic epithelium	UBERON:0000397	66.68	silver quality
lower esophagus	UBERON:0013473	66.53	gold quality
lower esophagus muscularis layer	UBERON:0035833	66.53	gold quality
transverse colon	UBERON:0001157	66.16	gold quality
right coronary artery	UBERON:0001625	65.69	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	65.36	gold quality
body of uterus	UBERON:0009853	65.20	gold quality
tibial artery	UBERON:0007610	64.42	gold quality
popliteal artery	UBERON:0002250	64.39	gold quality
right hemisphere of cerebellum	UBERON:0014890	64.17	gold quality
ectocervix	UBERON:0012249	64.05	gold quality
mucosa of transverse colon	UBERON:0004991	63.84	gold quality
hindlimb stylopod muscle	UBERON:0004252	63.52	gold quality
tibial nerve	UBERON:0001323	63.44	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.09

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• AFAP1-AS1 is a potential novel prognostic marker to predict the clinical outcome of pancreatic ductal adenocarcinoma patients after surgery (PMID:25925763)
• AFAP1-AS1 was the most significantly upregulated lncRNA in lung cancer. Elevated AFAP1-AS1 expression was associated with poor prognosis, suggesting that AFAP1-AS1 may be a useful biomarker for the prediction of lung cancer progression and prognosis. (PMID:26245991)
• AFAP1-AS1 expression was upregulated in NPC and associated with NPC metastasis and poor prognosis. In vitro experiments demonstrated that AFAP1-AS1 knockdown significantly inhibited the NPC cell migration and invasive capability. (PMID:26246469)
• LncRNA AFAP1-AS1 was up-regulated in non-small lung carcinoma tissues and it could be an independent prognostic indicator. (PMID:26463625)
• Three lncRNAs (AFAP1-AS1, UCA1, HOTAIR) were found to be deregulated in cisplatin-resistant esophageal squamous cell carcinoma compared with their parent cells. AFAP1-AS1 was significantly up-regulated in tumor tissues compared with adjacent normal tissues (P = 0.006). (PMID:26756568)
• Study showed that AFAP1-AS1 was remarkably increased in hepatocellular carcinoma (HCC) tissues and may promote the HCC development through upregulation of RhoA/Rac2 signaling. (PMID:26892468)
• AFAP1-AS1 is significantly up-regulated in colorectal cancer. (PMID:27261589)
• Results found that the expression of AFAP1-AS1 was dramatically upregulated in esophageal squamous cell carcinoma (ESCC) tissues and cell lines. Also, functional studies revealed that knockdown of AFAP1-AS1 expression in ESCC cells could result in diminished cell growth and increased apoptosis, which suggested that AFAP1-AS1 was a potential oncogene of ESCC. (PMID:27577754)
• AFAP1-AS1 was correlated with poor prognosis in gallbladder cancer patients. (PMID:27810781)
• This study suggests that AFAP1-AS1 and PD-1 may be potential therapeutic targets in nasopharyngeal carcinoma (PMID:28380458)
• Results indicate that circulating long non-coding RNAs (lncRNAs) MALAT1, AFAP1-AS1 and AL359062 may represent novel serum biomarkers for nasopharyngeal carcinoma (NPC) diagnosis and prognostic prediction after treatment. (PMID:28467811)
• SiRNA-mediated AFAP1-AS1 knockdown significantly decreased cell proliferation of the CCA cells, with downregulation of C-myc and Cyclin D1 in vitro. (PMID:28535506)
• Aberrant expression of lncRNA AFAP1-AS, a competing endogenous RNA of miR-181a, may involve in the onset and progression of Hirschsprung disease by augmenting the miR-181a target gene, RAP1B. (PMID:28924375)
• Knockdown of lncRNA AFAP1-AS1 significantly inhibited the cell proliferation and cell cycle progression. Moreover, reduced lncRNA AFAP1-AS1 also inhibited the cell invasion ability via regulating cell epithelial-mesenchymal transition (EMT) phenomenon in Gastric Cancer. (PMID:28975981)
• AFAP1-AS1 expression level was significantly elevated in non-small cell lung cancer patients compared with that in normal controls. (PMID:29080690)
• decreased cell migration in thyroid cancer as a result of down-regulation of AFAP1-AS1, is reported. (PMID:29331858)
• Results showed that expression of the lncRNA AFAP1-AS1 is upregulated in non-small cell lung cancer (NSCLC) tissues and cells, and associated with poor prognosis of NSCLC patients. The loss of AFAP1-AS1 inhibited NSCLC cell proliferation in vitro and suppressed tumor growth in vivo. Furthermore, AFAP1-AS1-mediated oncogenic effects occurred partially through epigenetic suppression of p21 expression by binding to EZH2. (PMID:29793547)
• Long noncoding RNA AFAP1-AS1 enhances cell proliferation and invasion in osteosarcoma through regulating miR-4695-5p/TCF4-beta-catenin signaling. (PMID:29901121)
• Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance. (PMID:29971915)
• Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis in breast cancer patients and regulated the breast cancer cells proliferation, apoptosis and metastasis. (PMID:29974352)
• LncRNA AFAP1-AS1 is an oncogene in tumors that have been studied so far, and it may act as a useful tumor biomarker and therapeutic target. (PMID:30173945)
• LncRNA AFAP1-AS1 facilitates the invasion of glioma cells and acts as an independent predictor of malignancy. (PMID:30178845)
• Expressions of AFAP1-AS1 were associated with pathological grade, TNM staging and metastatic potential of non-small cell lung cancer. AFAP1-AS1 could activate interferon regulatory factor (IRF)7, the retinoid-inducible protein (RIG)-I-like receptor signaling pathway and Bcl-2 in vitro. (PMID:30278439)
• This study demonstrates that AFAP1-AS1 acts as an oncogene in non-small cell lung cancer (NSCLC) to promote cell migration partly by upregulating AFAP1 expression, while its own expression is controlled by DNA methylation, and highlights its diagnostic and therapeutic values for NSCLC patients. (PMID:30293090)
• the IGF1R oncogene which is an important regulator of MEK/ERK signaling pathway, was positively regulated by AFAP1-AS1 through ameliorating miR-133a-mediated IGF1R repression in pancreatic cancer tissues. (PMID:30300116)
• AFAP1-AS1 functions as an endogenous RNA by competitively binding to miR-384 to regulate ACVR1, thus conferring inhibitory effects on pancreatic cancer cell stemness and tumorigenicity (PMID:30819221)
• our results provide the evidences that silencing of AFAP1-AS1 inhibits cell proliferation, EMT, and metastasis through PTEN-dependent signaling, and our findings elucidate a novel potential therapeutic target or biomarker for the treatment of ccRCC. (PMID:30832752)
• Findings showed that AFAP1-AS1 is upregulated in non-small-cell lung cancer (NSCLC) tissues and cells, and that high AFAP1-AS1 expression in NSCLC patients suggests worse outcomes. Furthermore, AFAP1-AS1 can promote NSCLC cell proliferation and migration through epigenetic silencing of tumor suppressor HBP1. (PMID:31069893)
• Long noncoding RNA AFAP1-AS1 accelerates the proliferation and metastasis of prostate cancer via inhibiting RBM5 expression. (PMID:31081081)
• LncRNA AFAP1-AS1 was upregulated in colorectal cancer (CRC) patients and was inversely correlated with GAS8-AS1 only in CRC patients but not in healthy controls. AFAP1-AS1 expression level increased with the increase of primary tumor diameters. (PMID:31132513)
• AFAP1-AS1 is overexpressed in osteosarcoma and plays an oncogenic role in osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway, in which RhoC acts as the interaction target of AFAP1-AS1. (PMID:31443665)
• AFAP1-AS1 regulates miR-512-3p, so as to realize the regulation effect on the proliferation. (PMID:31669642)
• Circulatinglong non-coding RNA FEZF1-AS1 and AFAP1-AS1 serve as potential diagnostic biomarkers for gastric cancer. (PMID:31785996)
• LncRNA AFAP1-AS1 promotes osteoblast differentiation of human aortic valve interstitial cells through regulating miR-155/SMAD5 axis. (PMID:31945413)
• WDFY3-AS2, BDNF-AS and AFAP1-AS1 as potential prognostic factors for patients with triple-negative breast tumors (PMID:32401758)
• LncRNA AFAP1-AS1 contributes to the progression of endometrial carcinoma by regulating miR-545-3p/VEGFA pathway. (PMID:32504788)
• LncRNA AFAP1-AS1 Knockdown Represses Cell Proliferation, Migration, and Induced Apoptosis in Breast Cancer by Downregulating SEPT2 Via Sponging miR-497-5p. (PMID:32955920)
• Involvement of the lncRNA AFAP1-AS1/microRNA-195/E2F3 axis in proliferation and migration of enteric neural crest stem cells of Hirschsprung’s disease. (PMID:32959905)
• LncRNA AFAP1-AS1 promotes proliferation ability and invasiveness of bladder cancer cells. (PMID:32964963)
• LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis. (PMID:33138677)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.